Category Archives: News

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

"MONTREAL , May 23, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, announced today that Ontario...

May 15, 2019: FDA approved venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

This is very big news. This is the first non-chemotherapy based fixed duration treatment for CLL in treatment naïve patients. Until this...

FDA places a partial hold on all venetoclax clinical trials for multiple myeloma (MM) patients

The U.S. Food and Drug Administration (FDA) put the partial hold on all MM trials when they did a pre-planned...

Venetoclax Will be Paid for in Australia

Venetoclax (Venclexta®), will be added to Australian Pharmaceutical Benefits Scheme (PBS) starting March 1, 2019. Venetoclax was developed in Australia and though...

CMS approves CAR-T therapy payment, but with significant strings attached

CMS is the the government agency that decides what gets paid for and what doesn't by Medicare and Medicaid. Often...

Bristol-Myers Squibb to Acquire Celgene

On Jan. 22, 2018, Celgene announced they had acquired Juno Therapeutics. Juno’s CAR-T, JCAR017, looks very promising in CLL and...

The FDA’s 10th approval of ibrutinib, this time in combination with obinutuzumab for frontline therapy for CLL

Today, Jan. 28., 2019, “FDA approved the use of IMBRUVICA® (ibrutinib) in combination with obinutuzumab (GAZYVA®) for adult patients with...

Duvelisib approved for Relapsed and Refractory CLL after failing 2 lines of therapy

For chronic lymphocytic leukemia patients, it is always good to have more options. The FDA’s approval of duvelisib, a very effective...